Consolidated Statements of Operations - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2025	Dec. 31, 2024
Product revenue		$ 704	$ 430
Operating expenses:
Cost of sales		646	270
Research and development		2,653	2,310
Sales and marketing		67	554
General and administrative	[1]	4,253	5,022
Total operating expenses		7,619	8,156
Operating loss		(6,915)	(7,726)
Other income (expense), net:
Interest income		37	32
Interest expense		(8)	(38)
Other income		17	0
Total other income (expense), net		46	(6)
Net loss		(6,869)	(7,732)
Foreign currency translation adjustments		(6)	(6)
Comprehensive loss		$ (6,875)	$ (7,738)
Net loss per common share, basic and diluted (in dollars per share)		$ (0.42)	$ (0.52)
Weighted average common shares outstanding, basic and diluted (in shares)		16,517,126	14,789,332

[1] Certain general and administrative costs (including executive compensation, corporate legal fees, audit fees, investor relations, and insurance) are shared across both segments. For internal reporting purposes, such costs are allocated to each segment based on an estimate of the proportion of management time and corporate resources utilized by each segment. Costs directly attributable to a segment are charged directly to that segment. For the years ended December 31, 2025 and 2024, the Regenerative Biotech segment bore substantially all general and administrative expense, as the Consumer Health Products segment incurred minimal shared corporate overhead.